Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization(1–3), wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pengfei, Nair, Manoj S., Liu, Lihong, Iketani, Sho, Luo, Yang, Guo, Yicheng, Wang, Maple, Yu, Jian, Zhang, Baoshan, Kwong, Peter D., Graham, Barney S., Mascola, John R., Chang, Jennifer Y., Yin, Michael T., Sobieszczyk, Magdalena, Kyratsous, Christos A., Shapiro, Lawrence, Sheng, Zizhang, Huang, Yaoxing, Ho, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852271/
https://www.ncbi.nlm.nih.gov/pubmed/33532778
http://dx.doi.org/10.1101/2021.01.25.428137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852271/
https://www.ncbi.nlm.nih.gov/pubmed/33532778
http://dx.doi.org/10.1101/2021.01.25.428137

Ejemplares similares